|recombinant human/mouse/rat follistatin-resistant activin A protein (Qk035)||£120.00 – £180.00|
Follistatin-resistant activin A (FRACTA) has been engineered to prevent binding to the natural inhibitor, follistatin. Activin A activity protein is regulated in vivo by follistatin, a high-affinity inhibitor; follistatin accumulates in stem cell culture, where it inhibits activin A.
Qk035 follistatin-resistant activin A (FRACTA) has equivalent bioactivity to wild-type activin A (Qk001) but does not bind follistatin so is resistant to feedback inhibition. High purity 26 kDa dimer comprising engineered mature domain of activin A protein, animal-free (AF) and carrier-protein free (CF). This specialised activin A has been developed in Marko Hyvönen’s group in the University of Cambridge.
|Show details||ipsc-esc-differentiation ipsc-esc-maintenance optimised-by-qkine pioneering-proteins|
|recombinant human R-spondin 1 LR5 protein (Qk031)||£120.00 – £750.00|
Recombinant R-spondin 1 LR5 protein is engineered to act as a high affinity ligand for the LGR5 receptor. In epithelial tissues LGR5 marks the stem cell population. This engineered protein, R-spondin 1 LR5, activates wnt signalling only in the LGR5+ stem cell population. R-spondin1 LR5 has been tested in intestinal organoid culture and supports organoid survival and growth. As LGR5 specifically marks stem cells and is not found on transit amplifying cells, the lower crypt multiplicity seen in organoid cultures with R-spondin 1 LR5 (in comparison to wild-type R-spondin 1, Qk006) supports the notion that this engineered form is acting specifically on stem cells. This specialized form of R-spondin 1 was developed in Marc de la Roche’s lab (University of Cambridge).
|Show details||ipsc-esc-differentiation ipsc-esc-maintenance optimised-by-qkine organoid pioneering-proteins r-spondins|